Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Lenograstim

Phase 1Protein / enzyme

Lenograstim is one of 90 small molecule programs targeting Efficacy. It is currently in Phase 1.

2

Indications

11

Total Trials

1

Active Trials

89

Competitors

Pipeline

Status by Indication[3][1]

Indication

EfficacyUnknown status

GrowthRecruiting

EfficacyPreclinical

Unknown status

GrowthPhase 1

Recruiting

Competition

Competitive Landscape

145 competitors in Efficacy

#DrugCompanyPhaseTrials

Rituxan

Oncovin

Adriamycin

Tivicay

Rogaine

Paraplatin

Alimta

Bystolic

VVitae Pharmaceuticals Inc., an Allergan affiliate

Pifeltro

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Platelet Rich Plasma

ZZagazig University

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Prostate Cancer1 trial

A Phase II Study Evaluating Intravenous Melphalan With Autologous Whole Blood Stem Cell Transplantation Over Three Cycles In Patients With Castration-Resistant Prostate Cancer (MEL-CAP)

Terminated·BBarts & The London NHS Trust·Phase 2/3·NCT01907009·29 enrolled

Multiple Myeloma1 trial

Study on the Incidence of Febrile Episodes During Stem Cells Collection After Chemotherapy in Patients With Multiple Myeloma

Unknown status·UUniversity of Pisa·Phase 3·NCT00932217·180 enrolled

Germ Cell Tumor1 trial

Gemcitabine, Paclitaxel, Ifosfamide, and Cisplatin in Treating Patients With Progressive or Relapsed Metastatic Germ Cell Tumors

Unknown status·UUniversity of Southampton·Phase 1/2·NCT00551122·23 enrolled

Maintenance Therapy1 trial

Trial Evaluating Induction Therapy With Idarubicin and Etoposide Plus Sequential or Concurrent Azacitidine and Maintenance Therapy With Azacitidine

Completed·UUniversity of Ulm·Phase 2·NCT01180322·277 enrolled

Growth1 trial

Donation of Whole Blood by Healthy Volunteers After Mobilisation by Haematopoietic Growth Factor (Rhu-G-CSF = Granocyte)

Recruiting·CCellProthera·Phase 1·NCT05594433·40 enrolled

6 more indications

Efficacy1 trial

Efficacy of Granulocyte-Colony Stimulating Factor (G-CSF)

Unknown status·DDERSHENG SUN·N/A·NCT03498248·155 enrolled

Acute Myeloid Leukemia1 trial

Azacytidine (Vidaza®) Versus Fludarabine and Cytarabine (Fluga Scheme) in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia

Completed·PPETHEMA Foundation·Phase 3·NCT02319135·289 enrolled

Advanced Stage1 trial

Bortezomib Plus CHOP Every 2 Weeks for Advanced Stage DLBCL

Completed·—·Phase 1/2·NCT00379574·49 enrolled

Neutropenia1 trial

A Clinical Trial of Patients With Solid Tumours Receiving Granulocyte Colony Stimulating Factor as Primary Prophylaxis for Chemotherapy-induced Neutropenia, in a Docetaxel Based Regimen

Completed· Sanofi logo

Sanofi·Phase 4·NCT01107756·403 enrolled

Diffuse Large B-Cell Lymphoma1 trial

Dose Dense Chemotherapy + Rituximab +/-Intensified High Dose Chemoimmunotherapy With Support of Peripheral Autologous Stem Cell in Diffuse Large B-Cell Lymphoma

Unknown status·FFondazione Italiana Linfomi - ETS·Phase 3·NCT00499018·399 enrolled

Lymphoproliferative Disease1 trial

Predictive Value of the "Cytocapacity Test" Patients With Lymphoproliferative Diseases and High-dose Therapy

Completed·WWiSP Wissenschaftlicher Service Pharma GmbH·Phase 2/3·NCT01085058·169 enrolled

Sources

References

[1]
ClinicalTrials.gov — 11 trial records for Lenograstim. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Lenograstim compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Lenograstim. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Sanofi company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Protein / enzyme[2]
Highest Phase: Phase 1[1]
Company: Sanofi

Related News